The US Food & Drug Administration should maintain constant communication with the public in the leadup to significant regulatory decisions – like the Aduhelm accelerated approval and the authorization of COVID-19 vaccine boosters – in order to combat the barrage of misinformation that muddles messages and damages the agency’s credibility, former deputy commissioner Josh Sharfstein said.
“The standard model for FDA is to wait until it makes a decision and then try to communicate that,” Sharfstein...